PBAC's latest decision on Tiotropium: Recommended (2024). Considered for Long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD) and treatment of severe asthma in adults and children aged 6–17 years.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
10
first 2016
Submissions
10
2016 → 2024
Eligible population
Adults with COPD or severe asthma requiring long-term maintenance treatment, and children aged 6–17 years with severe asthma meeting specific clinical criteria.
Therapy area
Respiratory
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
2 x single packs of tiotropium (Spiriva Respimat)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. The submission demonstrated nil net financial impact to PBS/RPBS, with no cost difference between 1 x double pack and 2 x single packs.
ICER (historical)
$15k/QALY–$45k/QALY in an earlier submission (2016) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2016: Recommended with restriction · Restricted — ICER $45k/QALY
Jul 2017: Not recommended · Restricted
Nov 2017: Not recommended · Restricted
Mar 2018: Recommended with restriction · Authority Required
Nov 2018: Recommended with restriction · Authority Required
Mar 2019: Recommended with restriction · Restricted